FindTrial
Sign In

CAT-8015 20 mcg/kg

DRUG2 trials

Sponsors

MedImmune LLC

Conditions

Chronic Lymphocytic LeukemiaLeukemia, Lymphoma, Chronic LymphocyticLeukemia, Prolymphocytic Leukemia, SmallLymphocytic Lymphoma, Moxetumomab PasudotoxNon-Hodgkin Lymphoma

Phase 1

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
TerminatedNCT00587457
MedImmune LLCLeukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
Start: 2007-03-07End: 2008-04-07Updated: 2017-07-06
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
CompletedNCT01030536
MedImmune LLCChronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Start: 2010-02-15End: 2013-03-04Updated: 2018-04-09

Related Papers

Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.
Journal of Clinical Oncology2019-05-20